Beyond weight loss: the long-term effects of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis and fibrosis regression
DOI:
https://doi.org/10.18203/2320-6012.ijrms20264196Keywords:
GLP-1 receptor agonists, Fibrosis regression, Metabolic dysfunction-associated steatotic liver disease, Metabolic dysfunction-associated steatohepatitis, Liver fibrosisAbstract
Metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), is characterized by hepatic steatosis, inflammation, and fibrosis. Although lifestyle modification is foundational, effective pharmacotherapy is needed, particularly for advanced fibrosis. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise beyond weight loss, but their long-term effects on fibrosis and underlying mechanisms remain unclear. This systematic review evaluates their effects on MASH and fibrosis, mechanisms of action, clinical evidence, and knowledge gaps. A systematic search of PubMed, Embase, Medline, and Cochrane Library identified randomized controlled trials and observational studies evaluating GLP-1 RAs in MASLD, reporting histological or non-invasive markers of fibrosis and steatosis. Comparisons with pioglitazone and vitamin E, alongside cardiovascular and metabolic outcomes, were assessed. GLP-1 RAs improved hepatic steatosis and inflammation, although fibrosis regression varied across trials, some demonstrated MASH resolution without worsening fibrosis, while others reported modest effects. Additional benefits included improvements in weight, glycemic control, lipid profiles, and cardiovascular risk factors. The contribution of direct hepatic versus weight-mediated effects remains unclear, and long-term safety in cirrhosis, including sarcopenia and worsening portal hypertension, requires further investigation. GLP-1 RAs offer promising hepatic and extrahepatic benefits in MASLD, but their effects on fibrosis require confirmation through larger, longer-term trials with robust histological endpoints. Combination therapy, long-term safety, and individualized treatment remain priorities for defining their role as first-line therapy.
Metrics
References
Wang S, Friedman SL. Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). Sci Translat Med. 2023;15(716):eadi0759. DOI: https://doi.org/10.1126/scitranslmed.adi0759
Luthra R, Sheth A. Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database. Adv Therapy, 2025;42(2):1165-95. DOI: https://doi.org/10.1007/s12325-024-03085-4
Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. Int J Molecular Sci. 2024;25(11):5640. DOI: https://doi.org/10.3390/ijms25115640
Eskridge W, Cryer DR, Schattenberg JM, Gastaldelli A, Malhi H, Allen AM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. J Clin Med. 2023;12(19):6216. DOI: https://doi.org/10.3390/jcm12196216
Radu F, Potcovaru CG, Salmen T, Filip PV, Pop C, Fierbințeanu-Braticievici C. The Link between NAFLD and Metabolic Syndrome. Diagnostics (Basel, Switzerland). 2023;13(4):614. DOI: https://doi.org/10.3390/diagnostics13040614
Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Current pharmaceutical design, 2010;16(17):1941-51. DOI: https://doi.org/10.2174/138161210791208875
Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 2015;14:121. DOI: https://doi.org/10.1186/s12944-015-0123-1
Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Molecular Hepatol. 2025;31(1):S32-50. DOI: https://doi.org/10.3350/cmh.2024.0431
Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195-200. DOI: https://doi.org/10.1001/jama.286.10.1195
Gancheva S, Roden M, Castera L. Diabetes as a risk factor for MASH progression. Diabetes Res Clin Pract. 2024;217:111846. DOI: https://doi.org/10.1016/j.diabres.2024.111846
Prabhakar O, Bhuvaneswari M. Role of diet and lifestyle modification in the management of nonalcoholic fatty liver disease and type 2 diabetes. Tzu Chi Med J. 2020;33(2):135-45. DOI: https://doi.org/10.4103/tcmj.tcmj_86_20
Wong V. Overview of Lean MASH and MASLD. Gastroenterol Hepatol. 2024;20(12):745-7.
Nguyen M, Asgharpour A, Dixon DL. Emerging therapies for MASLD and their impact on plasma lipids. Am J Prevent Cardiol. 2024;17:100638. DOI: https://doi.org/10.1016/j.ajpc.2024.100638
Hu Y, Sun C, Chen Y. Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease. J Clin Translat Hepatol. 2024;12(9):802-14. DOI: https://doi.org/10.14218/JCTH.2024.00123
Tincopa MA, Anstee QM, Loomba R. New and emerging treatments for metabolic dysfunction-associated steatohepatitis. Cell Metabolism. 2024;36(5):912-26. DOI: https://doi.org/10.1016/j.cmet.2024.03.011
Zhao J, Li B, Zhang K. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. Medicine. 2024;103(7):e37271. DOI: https://doi.org/10.1097/MD.0000000000037271
Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabol. 2018;27(4):740-56. DOI: https://doi.org/10.1016/j.cmet.2018.03.001
Mantovani A, Petracca G, Beatrice G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites. 2021;11(2):73. DOI: https://doi.org/10.3390/metabo11020073
Abdelmalek MF, Harrison SA, Sanyal AJ. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis. Diabetes Obes Metabol. 2024;26(6):2001-16. DOI: https://doi.org/10.1111/dom.15524
Mazhar IJ, Yasir M, Sarfraz S. Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease. Cureus. 2023;15(8):e43635. DOI: https://doi.org/10.7759/cureus.43635
Nevola R, Epifani R, Imbriani S, Giovanni T, Concetta A, Raffaele G, et al. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int J Molecular Sci. 2023;24(2):1703. DOI: https://doi.org/10.3390/ijms24021703
Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PloS one. 2023;18(8):e0289616. DOI: https://doi.org/10.1371/journal.pone.0289616
Rochoń J, Kalinowski P, Szymanek-Majchrzak K, Grat M. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J Gastroenterol. 2024;30(23):2964-80. DOI: https://doi.org/10.3748/wjg.v30.i23.2964
Taher J, Baker CL, Cuizon C, Hassan M, Rianna Z, Sarah F, et al. GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Molecular Metabol. 2024;3(9):823-33. DOI: https://doi.org/10.1016/j.molmet.2014.09.005
Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Therapeutic Adv Endocrinol Metabol. 2024;15:20420188231222367. DOI: https://doi.org/10.1177/20420188231222367
Luna-Marco C, de Marañon AM, Hermo-Argibay A. Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biol. 2023;66:102849. DOI: https://doi.org/10.1016/j.redox.2023.102849
Mashayekhi M, Nian H, Mayfield D. Weight loss-independent effect of liraglutide on insulin sensitivity in individuals with obesity and prediabetes. Diabetes. 2024;73(1):38-50. DOI: https://doi.org/10.2337/db23-0356
Marx N, Husain M, Lehrke M. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes. Circulation. 2022;146(24):1882-94. DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.059595
Ansari HUH, Qazi SU, Sajid F. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals with Obesity and Without Diabetes: A Systematic Review and Meta-Analysis. Endocrine Practice. 2024;30(2):160-71. DOI: https://doi.org/10.1016/j.eprac.2023.11.007
Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, Mohammad J, Stephen LA, Al-Rasadi K, el al. GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol. 2021;2021:8936865. DOI: https://doi.org/10.1155/2021/8936865
Bray JJH, Foster-Davies H, Salem A, Amy LH, Daniel RO, Julian PJH, et al. Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials. Diabetes Obesity Metabolism. 2021;23(8):1806-22. DOI: https://doi.org/10.1111/dom.14399
Huang HH, Wang YJ, Yu HW, Helen WY, Yin-Quan C, Arthur C, et al. Sarcopenia-related changes in serum GLP-1 level affect myogenic differentiation. J Cachexia Sarcopenia Muscle. 2024;15(5):1708-21. DOI: https://doi.org/10.1002/jcsm.13524
Morris SM, Armstrong MJ, Newsome PN. Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients with Cirrhosis. Clin Gastroenterol Hepatol. 2022;20(6):1120-222. DOI: https://doi.org/10.1016/j.cgh.2021.09.023
Bettge K, Kahle M, El Aziz AMS, Juris JM, Michael AN. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obesity Metabolism, 2016;19(3):336-47. DOI: https://doi.org/10.1111/dom.12824
Lutchman G, Modi A, Kleiner DE, Kittichai P, Theo H, Marc G, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007;46(2):424-9. DOI: https://doi.org/10.1002/hep.21661
Chee NMZ, Sinnanaidu RP, Chan WK. Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis. J Gastroenterol Hepatol, 2024;39(12):2545-54. DOI: https://doi.org/10.1111/jgh.16723
American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1):S59-85.
Nowak K, Łupina K, Romac A, Aleksandra K, Łucja I, Jakub J, et al. Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease. The Annals of pharmacotherapy. 2025;59(10):10600280251322002. DOI: https://doi.org/10.1177/10600280251322002
Kanwal F, Kramer JR, Li L, Yu-Xiao Y, Yumei C, Xian Y, et al. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Internal Med. 2024;184(11):1314-23. DOI: https://doi.org/10.1001/jamainternmed.2024.4661
Kanwal F, Shubrook JH, Adams LA, Kim P, Vincent WSW, Eugene W, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021;161(5):1657-69. DOI: https://doi.org/10.1053/j.gastro.2021.07.049
Barritt AS 4th, Marshman E, Noureddin M. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Alimentary Pharmacol Therap. 2022;55(8):944-59. DOI: https://doi.org/10.1111/apt.16794
Yabut JM, Drucker DJ. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Endocrine Rev. 2023;44(1):14-32. DOI: https://doi.org/10.1210/endrev/bnac018
Jianping W, Xuelian Z, Anjiang W. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis. J Clin Gastroenterol. 2021;55(7):586-93. DOI: https://doi.org/10.1097/MCG.0000000000001556
Scheen AJ. GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy. Drugs. 2024;84(11):1347-64. DOI: https://doi.org/10.1007/s40265-024-02090-9
Li C, Luo J, Jiang M. The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Front Pharmacol. 2022;13:838277. DOI: https://doi.org/10.3389/fphar.2022.838277
Yin YH, Sang LX, Chang B. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. World J Gastroenterol. 2023;29(48):6235-8. DOI: https://doi.org/10.3748/wjg.v29.i48.6235
Targher G, Mantovani A, Byrne CD, Tilg H. Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists. Gut. 2025;74(3):487-97. DOI: https://doi.org/10.1136/gutjnl-2024-334023
Havranek B, Loh R, Torre B, Rachel R, Dina HD. Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Scientific Rep. 2025;15(1):4947. DOI: https://doi.org/10.1038/s41598-025-89408-z
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Muhammad Hassan, Prarthna Shah, Behzad Maher, Donia Javidi, Mihir Patel, Maha Alhoda, Saba Iqbal, Ryan Stevens

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.